These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23017371)

  • 21. How Common Is Residual Inflammatory Risk?
    Ridker PM
    Circ Res; 2017 Feb; 120(4):617-619. PubMed ID: 28209792
    [No Abstract]   [Full Text] [Related]  

  • 22. Exploring new indications for statins beyond atherosclerosis: Successes and setbacks.
    Waters DD
    J Cardiol; 2010 Mar; 55(2):155-62. PubMed ID: 20206067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
    Albert MA; Staggers J; Chew P; Ridker PM;
    Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease.
    Undas A; Brozek J; Musial J
    Clin Lab; 2002; 48(5-6):287-96. PubMed ID: 12071579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Köenig W
    J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical value of drugs targeting inflammation for the management of coronary artery disease.
    Duchatelle V; Kritikou EA; Tardif JC
    Can J Cardiol; 2012; 28(6):678-86. PubMed ID: 22926034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein).
    Samson RH; Nair DG
    Semin Vasc Surg; 2011 Sep; 24(3):172-9. PubMed ID: 22153029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Correlation of high-sensitivity CRP concentration with the extent of coronary atherosclerosis in men with symptoms of ischemic heart disease].
    Piechota W; Piechota W
    Pol Merkur Lekarski; 2005 May; 18(107):511-5. PubMed ID: 16161944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular disease in chronic obstructive pulmonary disease.
    Hunninghake DB
    Proc Am Thorac Soc; 2005; 2(1):44-9. PubMed ID: 16113468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-reactive protein (CRP)-lowering agents.
    Prasad K
    Cardiovasc Drug Rev; 2006; 24(1):33-50. PubMed ID: 16939632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].
    Olsson AG
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435
    [No Abstract]   [Full Text] [Related]  

  • 32. Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.
    Sadowitz B; Maier KG; Gahtan V
    Vasc Endovascular Surg; 2010 May; 44(4):241-51. PubMed ID: 20403949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of biomarkers and genetics in peripheral arterial disease.
    McDermott MM; Lloyd-Jones DM
    J Am Coll Cardiol; 2009 Sep; 54(14):1228-37. PubMed ID: 19778662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?
    Schönbeck U; Libby P
    Circulation; 2004 Jun; 109(21 Suppl 1):II18-26. PubMed ID: 15173059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The time for cardiovascular inflammation reduction trials has arrived: how low to go for hsCRP?
    Ridker PM
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1222-4. PubMed ID: 18565847
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
    Field KM
    Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Markers of inflammation and their clinical significance.
    Ballantyne CM; Nambi V
    Atheroscler Suppl; 2005 May; 6(2):21-9. PubMed ID: 15823493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does reversal of oxidative stress and inflammation provide vascular protection?
    Koh KK; Oh PC; Quon MJ
    Cardiovasc Res; 2009 Mar; 81(4):649-59. PubMed ID: 19098298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients.
    Muhlestein JB
    Thromb Haemost; 2010 Jan; 103(1):71-82. PubMed ID: 20062914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anti-inflammatory effect of HMG-CoA reductase inhibitors].
    Kitamoto S; Egashira K
    Nihon Rinsho; 2004 Jan; 62(1):172-9. PubMed ID: 14737850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.